SLSong Liu

Song Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Song Liu has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoyue Wang

    State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730

    3 shared publications
  • Bill H. Diplas

    Department of Pathology, Duke University, Durham, North Carolina

    2 shared publications
  • Dingding Wang

    JST Sarcopenia Research Centre, National Center for Orthopaedics, Beijing Research Institute of Traumatology and Orthopaedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China

    2 shared publications
  • Hai Yan

    School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China

    2 shared publications
  • Hong Zhao

    Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310029, China

    2 shared publications
  • Jianmei Liu

    Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications

Latest Publications

  • Open Access

    Supplementary Figure S3 from Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition

    by Junbo Liang, Hong Zhao, Bill H. Diplas, Song Liu, Jianmei Liu, Dingding Wang, Yan Lu, Qing Zhu, Jiayu Wu, Wenjia Wang, et al.

    Supplementary Figure S3. Validation of ATRX synthetic lethal candidates by RNAi.

  • Open Access

    Supplementary Figure S3 from Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition

    by Junbo Liang, Hong Zhao, Bill H. Diplas, Song Liu, Jianmei Liu, Dingding Wang, Yan Lu, Qing Zhu, Jiayu Wu, Wenjia Wang, et al.

    Supplementary Figure S3. Validation of ATRX synthetic lethal candidates by RNAi.

  • Open Access

    Abstract 2703: Bioinformatics approaches to dissecting androgen receptor activity and cancer stemness during prostate cancer development and progression

    by Xiaozhuo Liu, Eduardo Cortes Gomez, Yibing Ji, Wanjun Song, Jun Yong, Jianmin Wang, Qiang Hu, Song Liu, Dean Tang

    Background: Cancer progression is generally accompanied by loss of differentiation and gain of stemness features. In prostate cancer (PCa), androgen receptor (AR) signaling at the transcription level has been reported to decline in high-grade vs. low-grade tumors. Also, loss of AR expression promotes a stem-like cell phenotype, implicating inverse relationship between AR signaling and stemness in PCa. Here, we aim to understand the dynamic changes in stem-like features and AR signaling activity (AR-A) at the global transcriptomic level, and the relationship between the AR-A and stemness, across the spectrum of PCa development and progression. Methods: We adapted and developed bioinformatic pipelines to assess the degree of cancer stemness (i.e., aggressiveness) and the AR-A during PCa development and progression. And the analysis was performed in published and in-house RNA-seq datasets encompassing normal prostate, primary PCa (TCGA), metastatic castration-resistant PCa (mCRPC), PCa with long-term or neo-adjuvant androgen-deprivation therapy (ADT), and castration-resistant xenografts models. Results: In the normal prostate, significantly higher AR-A and lower stemness were observed in luminal cells compared to basal cells, consistent with the knowledge that luminal cells are differentiated cells regulated by AR signaling whereas the basal cell compartment harbors stem cell activity. In PCa, we have observed that: 1). Surprisingly, both stemness and AR-A are significantly increased in primary PCa compared to benign prostates; 2). In untreated primary PCa, tumor progression is accompanied by significantly reduced AR-A and an increasing trend of stemness; 3). In mCRPC, the AR-A inversely correlates with stemness; 4). Interestingly, while long-term ADT leads to reduced AR-A and increased stemness, short-term ADT during neo-adjuvant therapy (i.e., before the surgery) results in decreased stemness; 5). Our xenograft CRPC models have confirmed the AR-A is significantly reduced in CRPC. Conclusions: PCa development and early growth are accompanied by increased AR-A as well as the stemness. In contrast, the progression of treatment-naïve PCa is accompanied by decreasing AR-A and increasing stemness. In treatment-failed mCRPC, the AR-A shows an inverse correlation with the stemness. Duration of ADT influences the stemness, and stemness functions as a factor of treatment-induced reprogramming. Significance: Developing gene signature scores to assess stemness and AR signaling has allowed us to track the global differentiation status of PCa, and to better understand the cancer cell heterogeneity and plasticity along the course of PCa development, progression and treatment resistance. Our results suggest that increased stemness represents a ‘universal’ feature of PCa progression and aggressiveness and should be therapeutically targeted. Citation Format: Xiaozhuo Liu, Eduardo Cortes Gomez, Yibing Ji, Wanjun Song, Jun Yong, Jianmin Wang, Qiang Hu, Song Liu, Dean Tang. Bioinformatics approaches to dissecting androgen receptor activity and cancer stemness during prostate cancer development and progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2703.

  • Open Access

    Next generation sequencing reveals novel alterations in B-cell heavy chain receptor repertoires associated with acute-on-chronic liver failure

    by Qiang Yan, Lei Wang, Liusheng Lai, Song Liu, Huaizhou Chen, Jiaxing Zhang, Yong Dai, Weiguo Sui

    Acute‑on‑chronic liver failure (ACLF) is a newly‑defined serious syndrome with major features of acute decompensation (AD) of hepatic cirrhosis, liver failure and failure of multiple other organs. To date, the mechanism underlying the development and progression of ACLF remains to be fully elucidated. It has been noted that ACLF is associated with immune dysregulation. However, studies have mainly focused on T‑cell responses. The present study aimed to determine the composition and alterations of B‑cell receptor (BCR) heavy chain repertoires associated with ACLF using next generation sequencing (NGS). A total of six patients with hepatitis B virus (HBV)‑related ACLF and six healthy control subjects were prospectively enrolled in the present study. The B‑cell immunoglobulin heavy chain (IGH) repertoires in peripheral blood mononuclear cells (PBMCs) obtained from the patients with HBV‑related ACLF and the control subjects were analyzed using NGS, coupled with multiplex polymerase chain reaction, were Illumina sequenced, and were further characterized using the international ImMunoGeneTics database. The distribution of the BCR complementarity‑determining region 3 (CDR3) variable (V), diversity (D) and joining (J) and V‑J gene segments were found to be comparable between the ACLF and control groups. Of note, the degree of clonal expansion in the ACLF group was significantly higher than that in the control group (P<0.05). Furthermore, a t‑test of the distribution ratio of the V, D, J and V‑J combinations in patients with ACLF and control subjects revealed differentially expressed genes. In total, six genes were upregulated and 19 genes were downregulated in response to ACLF. The difference between these two groups was statistically significant (P<0.05). The approach used in the present study was feasible and effective for analyzing peripheral B‑cell repertoires in HBV‑related ACLF. These results provide direct evidence that the BCR repertoire is important in immune responses, autoimmunity and alloreactivity, and that there is a link between the BCR repertoire and HBV‑ACLF. Therefore, ACLF‑specific BCR CDR3 sequences hold promise for therapeutic benefit to HBV‑ACLF in the future.


  • Open Access

    Systematic identification of regulatory variants associated with cancer risk

    by Song Liu, Yuwen Liu, Qin Zhang, Jiayu Wu, Junbo Liang, Shan Yu, Gong-Hong Wei, Kevin P. White, Xiaoyue Wang

    Most cancer risk-associated single nucleotide polymorphisms (SNPs) identified by genome-wide association studies (GWAS) are noncoding and it is challenging to assess their functional impacts. To systematically identify the SNPs that affect gene expression by modulating activities of distal regulatory elements, we adapt the self-transcribing active regulatory region sequencing (STARR-seq) strategy, a high-throughput technique to functionally quantify enhancer activities. From 10,673 SNPs linked with 996 cancer risk-associated SNPs identified in previous GWAS studies, we identify 575 SNPs in the fragments that positively regulate gene expression, and 758 SNPs in the fragments with negative regulatory activities. Among them, 70 variants are regulatory variants for which the two alleles confer different regulatory activities. We analyze in depth two regulatory variants—breast cancer risk SNP rs11055880 and leukemia risk-associated SNP rs12142375—and demonstrate their endogenous regulatory activities on expression of ATF7IP and PDE4B genes, respectively, using a CRISPR-Cas9 approach. By identifying regulatory variants associated with cancer susceptibility and studying their molecular functions, we hope to help the interpretation of GWAS results and provide improved information for cancer risk assessment.


  • Glypican-4 gene polymorphism (rs1048369) and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma

    by Danrui Zhao, Shuzhen Liu, Lingling Sun, Zhenzhen Zhao, Song Liu, Xiaojing Kuang, Jun Shu, Bing Luo


  • Open Access

    Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia

    by Norma J. Nowak, Sheila N.J. Sait, Amer Zeidan, George Deeb, Dan Gaile, Song Liu, LaurieAnn Ford, Paul K. Wallace, Eunice S. Wang, Meir Wetzler